| 【英語タイトル】Global Optic Nerve Disorders Treatment Market Size study & Forecast, by Treatment Type (Pharmacological and Surgery), by Indication (Optic Neuritis, Glaucoma, Congenital Optic Atrophy, Optic Neuropathy, and Others), by End-User (Hospitals, Clinics, Ambulatory Surgery Centers, and Others) and Regional Analysis, 2022-2029
|
 | ・商品コード：BZW23MA031
・発行会社（調査会社）：Bizwit Research & Consulting
・発行日：2023年4月17日
・ページ数：約200
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：アメリカ、カナダ、イギリス、ドイツ、フランス、スペイン、イタリア、中国、インド、日本、オーストラリア、韓国、ブラジル、メキシコ、中東
・産業分野：医療
|
◆販売価格オプション
（消費税別）
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
|
❖ レポートの概要 ❖
Bizwit Research社の本調査資料では、2021年に34億ドルであった世界の視神経疾患治療市場規模が、2022年〜2029年にかけて年平均XX%で成長すると予測しています。本資料は、視神経疾患治療の世界市場について市場実態を明らかにするとともに、今後の動向を展望したレポートです。エグゼクティブサマリー、市場定義・範囲、市場動向、産業分析、リスク分析（新型コロナウイルス感染症の影響）、治療別（薬理的、外科的）分析、適応症別（視神経炎、緑内障、先天性視神経萎縮症、視神経症、その他）分析、エンドユーザー別（病院、診療所、外来手術センター、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、その他地域）分析、競争分析、調査プロセスなどの項目で構成されています。また、主要参入企業として、Santen Pharmaceutical Co. Limited、Allergan Plc.、Novartis AG、 Pfizer, Inc.、 Bausch Health Companies, Inc.、 Aerie Pharmaceuticals, Inc.、 Teva Pharmaceutical Industries Ltd.,、Bionure Farma, S.L.、 Mallinckrodt Pharmaceuticals、AdvaCarePharmaなどの情報が含まれています。
・エグゼクティブサマリー
・市場定義・範囲
・市場動向
・産業分析
・リスク分析（新型コロナウイルス感染症の影響）
・世界の視神経疾患治療市場規模：治療別
- 薬理的治療の市場規模
- 外科的治療の市場規模
・世界の視神経疾患治療市場規模：適応症別
- 視神経炎の市場規模
- 緑内障の市場規模
- 先天性視神経萎縮症の市場規模
- 視神経症の市場規模
- その他適応症の市場規模
・世界の視神経疾患治療市場規模：エンドユーザー別
- 病院における市場規模
- 診療所における市場規模
- 外来手術センターにおける市場規模
- その他エンドユーザーにおける市場規模
・世界の視神経疾患治療市場規模：地域別
- 北米の視神経疾患治療市場規模
- ヨーロッパの視神経疾患治療市場規模
- アジア太平洋の視神経疾患治療市場規模
- 中南米の視神経疾患治療市場規模
- その他地域の視神経疾患治療市場規模
・競争分析
・調査プロセス |
Global Optic Nerve Disorders Treatment Market is valued at approximately USD 3.4 billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Optic Nerve Disorders can be defined as patterns of vision loss that are generally caused by developmental disorders or acquired disorders. Moreover, damage to an optic nerve or its pathways to the brain causes, loss of vision. There are different types of disorders that affect the optic nerve, including Coloboma of optic nerve, Glaucoma, Idiopathic intracranial hypertension, Neuromyelitis optica, Optic nerve atrophy, Optic nerve drusen, Optic nerve pit, Optic neuritis, Septo-optic dysplasia, and Toxic amblyopia (nutritional amblyopia) among others. The increasing incidence of glaucoma and growing number of aging populations are key factors driving the market growth.
The rising number of geriatric individuals is contributing towards the growth of the Global Optic Nerve Disorders Treatment Market. According to the World Bank Group, the world’s old population was 727 million in 2020, and it is predicted to treble over the next three decades, reaching 1.5 billion in 2050. Another important component driving space is growing incidences of glaucoma. For instance – World Glaucoma Association – in 2020, globally around 79.6 million individuals were affected by glaucoma in 2020, and as per projections, this number is likely to increase to 111.8 million individuals in 2040. Also, growing expansion of pharmaceutical and biotechnology industries and rising healthcare spending would create a lucrative growth prospectus for the market over the forecast period. However, the high cost of Optic Nerve Disorders Treatment stifles market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Optic Nerve Disorders Treatment Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to factors such as increase in healthcare spending by the governments of nations in these regions and rise in awareness about optic nerve disorders. Whereas Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, and presence of leading market players in the region.
Major market players included in this report are:
Santen Pharmaceutical Co. Limited
Allergan Plc.
Novartis AG
Pfizer, Inc.
Bausch Health Companies, Inc.
Aerie Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Ltd.,
Bionure Farma, S.L.
Mallinckrodt Pharmaceuticals
AdvaCarePharma
Recent Developments in the Market:
In August 2020, The FDA approved Enspryng (satralizumab-mwge) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults. NMOSD is a rare autoimmune disease of the central nervous system that mainly affects the optic nerves and spinal cord.
Global Optic Nerve Disorders Treatment Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Treatment Type, Indication, End-User, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Treatment Type
Pharmacological
Surgery
By Indication
Optic Neuritis
Glaucoma
Congenital Optic Atrophy
Optic Neuropathy
Others
By End-User
Hospitals
Clinics
Ambulatory Surgery Centers
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Optic Nerve Disorders Treatment Market, by Region, 2019-2029 (USD Billion)
1.2.2. Optic Nerve Disorders Treatment Market, by Treatment Type, 2019-2029 (USD Billion)
1.2.3. Optic Nerve Disorders Treatment Market, by Indication, 2019-2029 (USD Billion)
1.2.4. Optic Nerve Disorders Treatment Market, by End-User, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Optic Nerve Disorders Treatment Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Optic Nerve Disorders Treatment Market Dynamics
3.1. Optic Nerve Disorders Treatment Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Increasing incidence of glaucoma
3.1.1.2. Growing number of aging populations
3.1.2. Market Challenges
3.1.2.1. High cost associated with optic nerve disorders treatment
3.1.3. Market Opportunities
3.1.3.1. Growing expansion of pharmaceutical and biotechnology industries
3.1.3.2. Rising healthcare spending
Chapter 4. Global Optic Nerve Disorders Treatment Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. Industry Experts Prospective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Optic Nerve Disorders Treatment Market, by Treatment Type
6.1. Market Snapshot
6.2. Global Optic Nerve Disorders Treatment Market by Treatment Type, Performance – Potential Analysis
6.3. Global Optic Nerve Disorders Treatment Market Estimates & Forecasts by Treatment Type 2019-2029 (USD Billion)
6.4. Optic Nerve Disorders Treatment Market, Sub Segment Analysis
6.4.1. Pharmacological Treatment
6.4.2. Surgery
Chapter 7. Global Optic Nerve Disorders Treatment Market, by Indication
7.1. Market Snapshot
7.2. Global Optic Nerve Disorders Treatment Market by Indication, Performance – Potential Analysis
7.3. Global Optic Nerve Disorders Treatment Market Estimates & Forecasts by Indication 2019-2029 (USD Billion)
7.4. Optic Nerve Disorders Treatment Market, Sub Segment Analysis
7.4.1. Optic Neuritis
7.4.2. Glaucoma
7.4.3. Congenital Optic Atrophy
7.4.4. Optic Neuropathy
7.4.5. Others
Chapter 8. Global Optic Nerve Disorders Treatment Market, by End-User
8.1. Market Snapshot
8.2. Global Optic Nerve Disorders Treatment Market by End-User, Performance – Potential Analysis
8.3. Global Optic Nerve Disorders Treatment Market Estimates & Forecasts by End-User 2019-2029 (USD Billion)
8.4. Optic Nerve Disorders Treatment Market, Sub Segment Analysis
8.4.1. Hospitals
8.4.2. Clinics
8.4.3. Ambulatory Surgery Centers
8.4.4. Others
Chapter 9. Global Optic Nerve Disorders Treatment Market, Regional Analysis
9.1. Optic Nerve Disorders Treatment Market, Regional Market Snapshot
9.2. North America Optic Nerve Disorders Treatment Market
9.2.1. U.S. Optic Nerve Disorders Treatment Market
9.2.1.1. Treatment Type breakdown estimates & forecasts, 2019-2029
9.2.1.2. Indication breakdown estimates & forecasts, 2019-2029
9.2.1.3. End-User breakdown estimates & forecasts, 2019-2029
9.2.2. Canada Optic Nerve Disorders Treatment Market
9.3. Europe Optic Nerve Disorders Treatment Market Snapshot
9.3.1. U.K. Optic Nerve Disorders Treatment Market
9.3.2. Germany Optic Nerve Disorders Treatment Market
9.3.3. France Optic Nerve Disorders Treatment Market
9.3.4. Spain Optic Nerve Disorders Treatment Market
9.3.5. Italy Optic Nerve Disorders Treatment Market
9.3.6. Rest of Europe Optic Nerve Disorders Treatment Market
9.4. Asia-Pacific Optic Nerve Disorders Treatment Market Snapshot
9.4.1. China Optic Nerve Disorders Treatment Market
9.4.2. India Optic Nerve Disorders Treatment Market
9.4.3. Japan Optic Nerve Disorders Treatment Market
9.4.4. Australia Optic Nerve Disorders Treatment Market
9.4.5. South Korea Optic Nerve Disorders Treatment Market
9.4.6. Rest of Asia Pacific Optic Nerve Disorders Treatment Market
9.5. Latin America Optic Nerve Disorders Treatment Market Snapshot
9.5.1. Brazil Optic Nerve Disorders Treatment Market
9.5.2. Mexico Optic Nerve Disorders Treatment Market
9.5.3. Rest of Latin America Optic Nerve Disorders Treatment Market
9.6. Rest of The World Optic Nerve Disorders Treatment Market
Chapter 10. Competitive Intelligence
10.1. Top Market Strategies
10.2. Company Profiles
10.2.1. Santen Pharmaceuticals Co. Limited
10.2.1.1. Key Information
10.2.1.2. Overview
10.2.1.3. Financial (Subject to Data Availability)
10.2.1.4. Product Summary
10.2.1.5. Recent Developments
10.2.2. Allergan Plc.
10.2.3. Novartis AG
10.2.4. Pfizer, Inc.
10.2.5. Bausch Health Companies, Inc.
10.2.6. Aerie Pharmaceuticals, Inc.
10.2.7. Teva Pharmaceutical Industries Ltd.,
10.2.8. Bionure Farma, S.L.
10.2.9. Mallinckrodt Pharmaceuticals
10.2.10. AdvaCarePharma
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
11.3. Research Assumption
